Replies to post #237445 on Biotech Values

[DewDiligence]

Point Biopharma begins_Nasdaq_trading_tomorrow_with PNT ticker_symbol:

https://www.globenewswire.com/news-release/2021/06/30/2256054/0/en/POINT-Biopharma-Debuts-as-Publicly-Traded-Next-Generation-Radiotherapeutics-Company.html

[DewDiligence]

LLY acquires PNT for $12.50/sh cash—an 87% premium to yesterday’s close:

https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html

The nominal deal value is $1.4B; however, PNT has ~$800M in net cash and is due to receive at least $250M in milestone payments from LNTH, so LLY is not paying much for PNT’s radioligand pipeline.